ArticleBBA clinical2015
No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy.
Luísa Hoffmann et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it